Drug-eluting stent approved for peripheral arterial disease

November 16, 2012
Drug-eluting stent approved for peripheral arterial disease

(HealthDay)—The Zilver PTX Drug-Eluting Peripheral Stent has been approved by the U.S. Food and Drug Administration to treat peripheral arterial disease of the femoropopliteal artery.

The safety and effectiveness of the stent were evaluated in a clinical study of 479 people. After one year, 83 percent of narrowed arteries treated with the new stent were still open, compared with 33 percent in a control group, the FDA said.

The most common adverse reaction observed during the study was a re-narrowing of the affected artery, which required additional treatment to restore adequate blood flow.

Among those in whom the stent should not be used are women who are pregnant, breast-feeding, or who plan to become pregnant in the next five years, the FDA said.

Device maker Cook Inc., based in Bloomington, Ind., is required to conduct a five-year post-approval study involving some 900 people who have had the stent installed, the agency said.

Explore further: Drug-eluting balloons are a promising tool in treatment of narrowed metal stents

More information: The U.S. National Heart Lung and Blood Institute has more about peripheral arterial disease.

Related Stories

Glaucoma stent approved

June 26, 2012

(HealthDay) -- An ocular stent that's designed to reduce inner-eye pressure among people with mild or moderate open-angle glaucoma has been approved by the U.S. Food and Drug Administration.

Recommended for you

Scientists use 'virtual heart' to model heart failure

June 23, 2016

A team of researchers have created a detailed computational model of the electrophysiology of congestive heart failure, a leading cause of death. This "virtual heart" could help medical researchers study new drug therapies ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.